Request Demo
Zura Bio to Attend June 2024 Investor Conferences
7 June 2024
Zura Bio Limited (Nasdaq: ZURA), a clinical-stage company specializing in immunology, announced that its senior management will be participating in two key investor conferences this June. These events are significant opportunities for Zura Bio to engage with investors and discuss their innovative approaches to treating autoimmune and inflammatory diseases.
The first event is the Jefferies Global Healthcare Conference, where Michael Howell, Ph.D., the Chief Scientific Officer and Head of Translational Medicine at Zura Bio, will be holding one-on-one meetings. This conference is scheduled for Thursday, June 6, 2024, in New York, NY. These meetings will provide a platform for Dr. Howell to discuss the scientific advancements and clinical progress of Zura Bio's pipeline.
The second event is the Oppenheimer Novel Targets in Immunology Summit. Here, Robert Lisicki, the Chief Executive Officer of Zura Bio, will participate in a panel discussion titled “Novel Immunological Mechanisms for Dermatological Disorders.” Furthermore, he will also conduct one-on-one meetings on Monday, June 24, 2024, in New York, NY. This summit offers a crucial opportunity for Mr. Lisicki to present Zura Bio's strategic vision and innovative therapies targeting dermatological conditions.
Zura Bio is currently advancing three therapeutic assets, all of which have completed Phase 1/1b clinical studies and are ready to enter Phase 2 trials. The company’s portfolio includes tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880). These assets are being developed to address unmet medical needs in autoimmune and inflammatory diseases, with a focus on conditions such as systemic sclerosis.
The company's development strategy aims to prove the efficacy, safety, and convenience of these novel dual-pathway antibodies. By doing so, Zura Bio hopes to offer new therapeutic options for patients suffering from chronic and debilitating diseases.
Zura Bio's participation in these investor conferences underscores their commitment to transparency and engagement with the investor community. It also highlights the company’s focus on advancing innovative treatments that have the potential to significantly impact the lives of patients with autoimmune and inflammatory diseases.
The first event is the Jefferies Global Healthcare Conference, where Michael Howell, Ph.D., the Chief Scientific Officer and Head of Translational Medicine at Zura Bio, will be holding one-on-one meetings. This conference is scheduled for Thursday, June 6, 2024, in New York, NY. These meetings will provide a platform for Dr. Howell to discuss the scientific advancements and clinical progress of Zura Bio's pipeline.
The second event is the Oppenheimer Novel Targets in Immunology Summit. Here, Robert Lisicki, the Chief Executive Officer of Zura Bio, will participate in a panel discussion titled “Novel Immunological Mechanisms for Dermatological Disorders.” Furthermore, he will also conduct one-on-one meetings on Monday, June 24, 2024, in New York, NY. This summit offers a crucial opportunity for Mr. Lisicki to present Zura Bio's strategic vision and innovative therapies targeting dermatological conditions.
Zura Bio is currently advancing three therapeutic assets, all of which have completed Phase 1/1b clinical studies and are ready to enter Phase 2 trials. The company’s portfolio includes tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880). These assets are being developed to address unmet medical needs in autoimmune and inflammatory diseases, with a focus on conditions such as systemic sclerosis.
The company's development strategy aims to prove the efficacy, safety, and convenience of these novel dual-pathway antibodies. By doing so, Zura Bio hopes to offer new therapeutic options for patients suffering from chronic and debilitating diseases.
Zura Bio's participation in these investor conferences underscores their commitment to transparency and engagement with the investor community. It also highlights the company’s focus on advancing innovative treatments that have the potential to significantly impact the lives of patients with autoimmune and inflammatory diseases.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.